Pre-Annual General Meeting Information • Sep 22, 2021
Pre-Annual General Meeting Information
Open in ViewerOpens in native device viewer
If you are in any doubt about the contents of this document or what action you should take, you are recommended to seek your own personal financial advice from an appropriately qualified independent adviser authorised under the Financial Services and Markets Act 2000 if in the United Kingdom or otherwise regulated under the laws of your own country.
If you have recently sold or transferred all of your ordinary shares of 1 penny each in the capital of Darktrace ("Shares" and each holder, a "Shareholder"), please forward this document, together with any accompanying documents, as soon as possible either to the purchaser or transferee or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the Shares.
(incorporated in England and Wales with registered number 13264637)
This document should be read in its entirety. Your attention is drawn to the letter from the Chair set out in Darktrace's annual report for the year ended 30 June 2021 available on Darktrace's website at www.darktrace.com. Your Board is unanimously recommending that you vote in favour of Resolutions 1 – 20 set out in the notice of Annual General Meeting referred to below.
Notice of the annual general meeting ("AGM") of Darktrace to be held at 9.00 a.m. (UK time) on 24 November, 2021, at the offices of Latham & Watkins 99 Bishopsgate, London EC2M 3XF is set out in this document.
Shareholders will find enclosed a Form of Proxy for use at the AGM. To be valid for use at the AGM, the Form of Proxy must be completed and returned, in accordance with the instructions printed thereon, to Darktrace's share registrar, Equiniti Limited, as soon as possible and, in any event, to arrive by 9.00 a.m (UK time) on 22 November 2021. The completion and return of a Form of Proxy will not preclude Shareholders from attending and voting in person at the AGM should they subsequently wish to do so.
Shareholders should submit their votes via proxy as early as possible. Further instructions on completion of the form of proxy are set out in the 'Notes' section of this document. CREST members may also vote electronically through the CREST electronic proxy appointment service. In addition, Forms of Proxy can also be submitted by Shareholders electronically (even outside CREST) by visiting www.sharevote.co.uk or emailing a scanned copy of the signed personalised Form of Proxy to [email protected]. Please contact the Equiniti helpline on 0371 384 2030 for any further guidance.
NOTICE IS HEREBY GIVEN that the Annual General Meeting of Darktrace will be held at 9.00 a.m. (UK time) on 24 November, 2021, at the offices of Latham & Watkins 99 Bishopsgate, London EC2M 3XF for the purpose of considering and, if thought fit, passing the following resolutions. Resolutions 1 to 16 are proposed as ordinary resolutions. This means that for each of those resolutions to be passed, more than half of the votes must be cast in favour of the resolution. Resolutions 17 to 20 are proposed as special resolutions. This means that for each of those resolutions to be passed, at least three-quarters of the votes cast must be in favour of the resolution.
13.1 up to a maximum aggregate nominal amount equal to £4,650,912.69 (being equal to twothirds of the nominal value of Darktrace's current issued share capital), such amount to be reduced by the nominal amount of any Relevant Securities allotted pursuant the authority in paragraph 13.2, in connection with an offer by way of a rights issue:
13.1.1 to holders of Shares in proportion (as nearly as may be practicable) to their respective holdings; and
but subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to treasury shares, fractional entitlements, record dates, legal or practical problems in or under the laws of any territory or the requirements of any regulatory body or stock exchange; and
13.2 in any other case, up to an aggregate nominal amount of £2,325,456.34 (being equal to onethird of the nominal value of Darktrace's current issued share capital), such amount to be reduced by the nominal amount of any equity securities allotted pursuant to the authority in paragraph 13.1 above in excess of £2,325,456.34,
provided that such authority shall expire (unless previously revoked by Darktrace) at the conclusion of the next annual general meeting of Darktrace after passing of this resolution or 31 March 2023, whichever is earlier, save that in each case Darktrace may, before such expiry, make an offer or agreement which would or might require equity securities to be granted after the authority has expired and the Directors may allot equity securities in pursuance of any such offer or agreement notwithstanding that this authority has expired.
17.1.2 holders of other equity securities, if this is required by the rights of those securities or, if the Directors consider it necessary,
but subject to such exclusions or other arrangements as the Directors may consider necessary, expedient or appropriate in relation to treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or under the laws of, any territory (including the requirements of any regulatory body or stock exchange) or any other matter; and
17.2 otherwise than pursuant to 17.1 above, the allotment of further equity securities up to an aggregate nominal amount of £348,818.45 (representing no more than five per cent. of the current issued share capital of Darktrace),
such authority shall expire (unless previously revoked by Darktrace) at the conclusion of the next annual general meeting of Darktrace after this resolution is passed or 31 March 2023, whichever is earlier, save that in each case, Darktrace may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted (or treasury shares to be sold) after the authority expires and the Directors may allot equity securities (or sell treasury shares) in pursuance of any such offer or agreement as if this authority had not expired.
such authority shall expire (unless previously revoked by Darktrace) at the conclusion of the next annual general meeting of Darktrace after this resolution is passed or 31 March 2023, whichever is earlier, save that in each case, Darktrace may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted (or treasury shares to be sold) after the authority expires and the Directors may allot equity securities (or sell treasury shares) in pursuance of any such offer or agreement as if this authority had not expired.
19.1 to a maximum number of Shares with an aggregate nominal value of up to £697,636.90 (amounting to 69,763,690 Shares as at the date of the notice) representing 10 per cent. of the current issued share capital of Darktrace;
19.2 by the condition that Darktrace does not pay less (exclusive of expenses) for each Share than the nominal value of such Share and the maximum price which may be paid for a Share (exclusive of expenses) is the higher of:
such authority shall expire at the conclusion of the next annual general meeting of Darktrace or (if earlier), unless previously revoked, varied or renewed, provided that if Darktrace has agreed before such expiry to purchase Shares where these purchases will or may be executed (either wholly or in part) after the authority terminates Darktrace may complete such a purchase as if the authority conferred hereby had not expired.
These notes explain the proposed Resolutions.
Resolutions 1 to 16 are proposed as ordinary resolutions, which means that for each of those Resolutions to be passed, more than half the votes cast must be in favour of the Resolution. Resolutions 17 to 20 are proposed as special resolutions, which means that for each of those Resolutions to be passed, at least 75% of the votes cast must be in favour of the Resolution.
In this notice, references to the "current issued share capital of Darktrace" are to the 697,636,903 issued ordinary shares of £0.01 each in the capital of Darktrace as at the close of business on 20 September, 2021 (being the latest practicable date before the publication of this document).
The Directors must present the report of the Directors and the accounts of Darktrace for the year ended 30 June 2021 to Shareholders at the AGM. The Board asks that Shareholders receive the reports of the Directors and the financial statements for the year ended 30 June 2021, together with the report of the auditor.
Shareholders are required to appoint the auditor at each annual general meeting at which audited accounts are presented to Shareholders. Resolution 2 proposes the appointment of Grant Thornton LLP as the auditor of Darktrace and to hold office until the conclusion of the next annual general meeting of Darktrace at which accounts are laid.
It is also normal practice for the Directors to be authorised to determine the level of the auditor's remuneration for the ensuing year. Shareholders are being asked to authorise the Directors to determine PricewaterhouseCoopers LLP's remuneration as auditors.
In accordance with the UK Corporate Governance Code, all of the Directors of Darktrace will retire (or their appointment will otherwise terminate) at the AGM and offer themselves for re-election. Resolutions 4 to 12 seek your approval to re-elect the relevant individuals as Directors. The biographies of each of these Directors are included in the 2021 annual report and accounts at pages 64 to 66.
The Nomination Committee identifies, evaluates and recommends to the Board candidates for appointment and reappointment as directors. Appointments are made on merit and candidates are considered against objective criteria, having regard to the benefits of the diversity of the Board and the Committee keeps diversity, mix of skills, experience and knowledge of the Board under review. The Board has confirmed that each of the Directors seeking re-election continue to perform effectively and demonstrate commitment to the role. The Board considers that they each provide distinct and valuable input to the overall operation of the Board.
Having considered the performance and contribution of each of the Independent Non-Executive Directors, the Board considers that each of the Independent Non-Executive Directors continues to be effective and to demonstrate commitment to the role. Taking into consideration the guidance provided by the UK Corporate Governance Code, along with the experience and standing of each of the Independent Non-Executive Directors, the Board is satisfied that each of the Independent Non-Executive Directors offering themselves for election and re-election is independent in character and judgement and there are no relationships or circumstances which are likely to affect their character or judgement. Gordon Hurst, the non-executive Chair was also considered independent upon appointment.
Darktrace requires the flexibility to allot Shares from time to time. The Directors will be limited as to the number of Shares they can at any time allot because allotment authority is required under the Act, save in respect of employee share schemes.
The Directors' existing authority to allot "relevant securities" (including Shares and/or rights to subscribe for or convert into Shares), which was granted (pursuant to section 551 of the Act) at the general meeting held on 29 April 2021, will expire at the end of this year's AGM. Accordingly, Resolution 13 would renew and increase this authority (until the next annual general meeting or unless such authority is revoked or renewed prior to such time) by authorising the Directors (pursuant to section 551 of the Act) to allot relevant securities. Resolution 13.1 will allow Darktrace to allot Shares and to grant rights to subscribe for or to convert any security into Shares up to an aggregate nominal amount of £4,650,912.69 representing approximately two-thirds of the current issued ordinary share capital of Darktrace. This maximum is reduced by the nominal amount of any Relevant Securities allotted pursuant the authority in paragraph 13.2 in line with the guidance issued by the Investment Association, up to an aggregate nominal amount of £2,325,456.34 representing one-third of the current issued ordinary share capital of Darktrace (excluding treasury shares).
Save in respect of the issue of new Shares pursuant to Darktrace's share option scheme, the Directors currently have no plans to allot relevant securities, but the Directors believe it to be in the interests of Darktrace for the Board to be granted this authority, to enable the Board to take advantage of appropriate opportunities which may arise in the future.
Darktrace held no Shares in treasury as at 20 September, 2021 being the last practicable date prior to publication of this document.
In line with section 439 of the Act, Resolution 14 seeks to approve the Report of the Remuneration Committee, which may be found on pages 82 to 98 of the annual report and which gives details of the Directors' remuneration for the year ended 30 June 2021. The vote on this Resolution 14 is advisory and does not affect the future remuneration paid to any Director. This resolution does not relate to the Annual Report on Remuneration set out on pages 98 to 110 of the Report and Accounts and proposed in Resolution 15.
In line with section 439A of the Act, Resolution 15 seeks to approve the Annual Report on Remuneration, which may be found on pages 98 to 110 of the annual report and which provides details of Darktrace's remuneration framework. No remuneration will be paid or payment for loss of office made to former, current or prospective Directors unless permitted by the policy. The vote on this Resolution is binding.
Resolution 16 will be proposed as an ordinary resolution to authorise Darktrace to make political donations and incur political expenditure for the period from the date of the AGM to the conclusion of the next annual general meeting up to a maximum aggregate amount of £100,000.
Part 14 of the Act requires companies to obtain the approval of Shareholders before political donations exceeding £5,000 in aggregate in any 12-month period are made to (i) political parties, (ii) other political organisations, and (iii) independent election candidates.
Although Darktrace does not make what are usually regarded as political donations, it may incur expenditure on such items as sponsorship or attendance at political discussions organised by political parties on a non-partisan basis in order to make them aware of industry trends and key arguments affecting our industry. Some of these activities may be caught by the broad definitions in the Act, and this resolution is being proposed on a precautionary basis to allow Darktrace to continue its current activities.
The Act provides that if Darktrace allots new Shares or sells treasury Shares for cash, it must first offer these securities to existing Shareholders in proportion to their existing holdings, unless such pre-emption rights are disapplied by Shareholders under the Act. The authority given to the Directors at the general meeting held on 29 April 2021 to allot shares for cash on a non-pre-emptive basis pursuant to the Act expires on the date of the AGM.
Resolution 17 will authorise the Directors to allot equity securities or sell pursuant to the authority given under Resolution 13 for cash in connection with (i) a pre-emptive offer, or (ii) on a non-pre-emptive basis up to a maximum aggregate nominal amount of £348,818.45, representing approximately five per cent. of Darktrace's current issued ordinary share capital, in each case without the Shares first being offered to existing Shareholders in proportion to existing holdings. Save in respect of the issue of new Shares pursuant to Darktrace's share option scheme, the Directors have no present intention of exercising this authority.
This resolution is in line with guidance issued by the Investment Association (as updated in July 2016) and the Pre-Emption Group's Statement of Principles (as updated in March 2015) (the Statement of Principles), and the template resolutions published by the Pre-Emption Group in May 2016. The Preemption Principles allow the authority for an issue of shares otherwise than in connection with a pre-emptive offer to be increased from five per cent. to 10 per cent. of Darktrace's issued ordinary share capital, provided that Darktrace confirms that it intends to use the additional five per cent. authority only in connection with an acquisition or specified capital investment. Resolution 18 will additionally authorise the Board to allot new Shares (or sell treasury Shares) for cash, without the Shares first being offered to existing Shareholders in proportion to their existing holdings, up to a nominal amount of £348,818.45 (that is approximately five per cent. of Darktrace's current issued ordinary share capital) in connection with an acquisition or specified capital investment which is announced contemporaneously with the issue, or which has taken place in the preceding six-month period and is disclosed in the announcement of the issue.
The Board also confirms, in accordance with the Pre-emption Principles, that it does not intend to issue Shares for cash representing more than 7.5 per cent. of Darktrace's issued ordinary share capital in any rolling three-year period other than to existing shareholders, save as permitted in connection with an acquisition or specified capital investment as described above, without prior consultation with shareholders.
The authorities granted under Resolutions 17 and 18 will expire at the end of the next AGM.
The articles of association of Darktrace do not contain a restriction on Darktrace's ability to purchase its own Shares (subject to statutory requirements). This Resolution seeks to grant the Directors authority (until the next annual general meeting or (if earlier), unless such authority is revoked or renewed from time to time) to make market purchases of Darktrace's own Shares with an aggregate nominal value of up to £697,636.90 (amounting to 69,763,690 Shares as at the date of the notice) representing 10 per cent. of the current issued share capital of Darktrace.
The maximum price payable for each Share would be an amount equal to the higher of (a) five per cent. over the average market value of the Shares for the five Business Days (being any day other than a Saturday or Sunday on which banks are open for normal banking business in London) immediately preceding the date on which Darktrace agrees to buy the Shares concerned, based on the share price published in the Daily Official List of the London Stock Exchange plc; and (b) an amount equal to the higher of the price of the last independent trade and the highest current independent bid at the time on the trading venue where the purchase is carried out. The minimum price would be the nominal value of £0.01 per Share, being the nominal value of the Shares.
Subject to resolution 19 being passed, the Directors may repurchase Shares and the Directors consider that it is in the best interests of Darktrace and its Shareholders to keep the ability to make market purchases of Darktrace's own Shares in appropriate circumstances, without the cost and delay of a general meeting. The authority would only be exercised if the Directors believe the purchase would enhance earnings per Share and be in the best interests of Shareholders generally. Subject to Darktrace's obligations under the Listing Rules and the UK version of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse (Market Abuse Regulation), as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, the Directors reserve the right to purchase Darktrace's Shares otherwise than in accordance with Article 5 of MAR.
Darktrace may either cancel any Shares it purchases under this authority or transfer them into treasury (and subsequently sell or transfer them out of treasury or cancel them).
Section 307A of the Act provides that a general meeting of a 'traded company' must be called by at least 21 days' notice but may be called by at least 14 days' notice if three conditions are met. The three conditions are that:
Resolution 20 is proposed to authorise Darktrace to hold general meetings on 14 clear days' notice. The notice period required by the Act for general meetings of Darktrace is 21 days, unless Shareholders approve a shorter notice period, which cannot be less than 14 clear days. AGMs must always be held on at least 21 clear days' notice.
The Directors consider it desirable that they have the option to call general meetings of Darktrace, other than the AGM, on at least 14 clear days' notice if there are circumstances where that is appropriate. The Directors will only use such authority when to do so would clearly be advantageous to shareholders as a whole and the matter to be considered is time sensitive and in accordance with the requirements of the Act.
Resolution 20, which will be proposed as a special resolution, will implement this proposal and the authority of this resolution will expire at the conclusion of the next annual general meeting to be held in 2021 when it is intended that a similar resolution will be proposed in order to renew this authority.
The Directors believe that the proposed Resolutions 1 – 20 to be considered at the AGM are in the best interests of Darktrace and its Shareholders as a whole and therefore, the Directors unanimously recommend that you vote in favour of the Resolutions, as they intend to do in respect of their own beneficial holdings, totalling 10,727,440 Shares, in aggregate, and representing 1.54% of the current issued ordinary share capital of Darktrace as at 20 September, 2021 being the last practicable date prior to publication of this document.
Registered Office: By Order of the Board Maurice Wilkes Building St John's Innovation Park Cowley Road, Cambridge United Kingdom, CB4 0DS
Dated 22 September 2021 James Sporle
Company Secretary
(h) CREST members and, where applicable, their CREST sponsors, or voting service providers should note that Euroclear UK & Ireland Limited does not make available special procedures in CREST for any particular message. Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member, or sponsored member, or has appointed a voting service provider, to procure that his/her CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.
(i) Darktrace may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.
Whichever form of communication is chosen, the request must either set out the statement in full or, if supporting a statement sent by another member, clearly identify the statement which is being supported, and be received by Darktrace at least one week before the AGM.
(s) Copies of this document will be available free of charge during normal business hours on weekdays (excluding Saturday, Sunday and public holidays) from the date hereof until 24 November 2021 from Darktrace's Registered Office. Copies will also be available to download from Darktrace's website at https://www.darktrace.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.